Insider · CIK 1681643
Huda Y Zoghbi
Director at Regeneron Pharmaceuticals REGN
Full history from EDGAR: holdings now, every transaction and Form 144 planned sales
Open-market buys0
Open-market sales36
Bought$0
Sold$19.1M
Every trade, with what the company filed around it
Open-market buys and sales as each Form 4 states them, newest first.
How these figures work
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.
| Date | Company | Trade | Value | Holding after | Notes |
|---|---|---|---|---|---|
| Nov 3, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 7,439 sh at $380.95 The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. | $2.8M | 9,142 | The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. |
| Nov 3, 2026 | Regeneron Pharmaceuticals REGN | Sold 6,939 sh at $970.42 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. | $6.7M | 2,203 −76% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. |
| Nov 3, 2026 | Regeneron Pharmaceuticals REGN | Sold 500 sh at $971.06 The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. | $486K | 1,703 −23% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 3, 2026. |
| Aug 10, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 800 sh at $376.69 The same day as a Form 144 notice of a planned insider sale filed Aug 10, 2026. | $301K | 2,503 | The same day as a Form 144 notice of a planned insider sale filed Aug 10, 2026. |
| Aug 10, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 800 sh at $800.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Aug 10, 2026. | $640K | 1,703 −32% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Aug 10, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Option exercise 1,638 sh at $376.69 The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $617K | 3,341 | The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 49 sh at $774.68 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $38K | 3,292 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 50 sh at $775.50 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $39K | 3,242 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 53 sh at $778.47 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $41K | 3,189 −2% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 208 sh at $779.55 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $162K | 2,981 −7% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 331 sh at $780.45 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $258K | 2,650 −11% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 209 sh at $781.28 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $163K | 2,441 −8% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 298 sh at $782.10 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $233K | 2,143 −12% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 220 sh at $783.29 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $172K | 1,923 −10% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 160 sh at $784.45 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $126K | 1,763 −8% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 56 sh at $785.61 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $44K | 1,707 −3% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Feb 19, 2026 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 4 sh at $790.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. | $3K | 1,703 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. The same day as a Form 144 notice of a planned insider sale filed Feb 19, 2026. |
| Jan 2, 2026 | Regeneron Pharmaceuticals REGN | Award 155 sh 43 days after a Form 144 notice of a planned insider sale filed Nov 20, 2025. | 1,703 | 43 days after a Form 144 notice of a planned insider sale filed Nov 20, 2025. | |
| Jan 2, 2025 | Regeneron Pharmaceuticals REGN | Award 166 sh 63 days after the company's 10-Q filed Oct 31, 2024. | 1,548 | 63 days after the company's 10-Q filed Oct 31, 2024. | |
| Jan 2, 2024 | Regeneron Pharmaceuticals REGN | Option exercise 1,117 sh at $391.92 61 days after the company's 8-K filed Nov 2, 2023. | $438K | 2,364 | 61 days after the company's 8-K filed Nov 2, 2023. |
| Jan 2, 2024 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,117 sh at $900.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 61 days after the company's 8-K filed Nov 2, 2023. | $1M | 1,247 −47% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 61 days after the company's 8-K filed Nov 2, 2023. |
| Jan 2, 2024 | Regeneron Pharmaceuticals REGN | Award 135 sh 61 days after the company's 8-K filed Nov 2, 2023. | 1,382 | 61 days after the company's 8-K filed Nov 2, 2023. | |
| Oct 13, 2023 | Regeneron Pharmaceuticals REGN | Option exercise 1,000 sh at $391.92 8 days after the company's 8-K filed Oct 5, 2023. | $392K | 2,247 | 8 days after the company's 8-K filed Oct 5, 2023. |
| Oct 13, 2023 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,000 sh at $850.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. 8 days after the company's 8-K filed Oct 5, 2023. | $850K | 1,247 −45% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. 8 days after the company's 8-K filed Oct 5, 2023. |
| Jan 3, 2023 | Regeneron Pharmaceuticals REGN | Award 165 sh | 1,247 | ||
| Mar 16, 2022 | Regeneron Pharmaceuticals REGN | Option exercise 2,000 sh at $391.92 | $784K | 3,082 | |
| Mar 16, 2022 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 2,000 sh at $675.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1.4M | 1,082 −65% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jan 3, 2022 | Regeneron Pharmaceuticals REGN | Award 191 sh | 1,082 | ||
| Sep 14, 2021 | Regeneron Pharmaceuticals REGN | Option exercise 998 sh at $391.92 | $391K | 1,889 | |
| Sep 14, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 998 sh at $650.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $649K | 891 −53% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Sep 13, 2021 | Regeneron Pharmaceuticals REGN | Option exercise 2 sh at $391.92 | $784 | 893 | |
| Sep 13, 2021 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 2 sh at $651.10 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1K | 891 −<1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jan 4, 2021 | Regeneron Pharmaceuticals REGN | Award 248 sh | 891 | ||
| Jul 7, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 1,706 sh at $391.92 | $669K | 2,349 | |
| Jul 7, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,706 sh at $650.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1.1M | 643 −73% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 11, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 1,706 sh at $391.92 | $669K | 2,349 | |
| Jun 11, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 1,706 sh at $625.00 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $1.1M | 643 −73% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 1,706 sh at $391.92 | $669K | 2,349 | |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 149 sh at $606.64 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $90K | 2,200 −6% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 251 sh at $607.64 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $153K | 1,949 −11% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 330 sh at $608.62 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $201K | 1,619 −17% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 161 sh at $609.48 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $98K | 1,458 −10% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 202 sh at $610.41 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $123K | 1,256 −14% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 164 sh at $611.46 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $100K | 1,092 −13% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 265 sh at $612.52 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $162K | 827 −24% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 5 sh at $613.03 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $3K | 822 −1% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 80 sh at $615.28 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $49K | 742 −10% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| Jun 10, 2020 | Regeneron Pharmaceuticals REGN | Sold (10b5-1) 99 sh at $616.19 The filing says this sale was under a Rule 10b5-1 plan set up in advance. | $61K | 643 −13% | The filing says this sale was under a Rule 10b5-1 plan set up in advance. |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Option exercise 5,118 sh at $391.92 | $2M | 5,761 | |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Sold 1,722 sh at $565.64 The filing does not mark this sale as under a Rule 10b5-1 plan. | $974K | 4,039 −30% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Sold 2,128 sh at $566.37 The filing does not mark this sale as under a Rule 10b5-1 plan. | $1.2M | 1,911 −53% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Sold 646 sh at $567.58 The filing does not mark this sale as under a Rule 10b5-1 plan. | $367K | 1,265 −34% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Sold 609 sh at $568.37 The filing does not mark this sale as under a Rule 10b5-1 plan. | $346K | 656 −48% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| May 7, 2020 | Regeneron Pharmaceuticals REGN | Sold 13 sh at $569.20 The filing does not mark this sale as under a Rule 10b5-1 plan. | $7K | 643 −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. |
| Jan 2, 2020 | Regeneron Pharmaceuticals REGN | Award 320 sh | 643 | ||
| Jan 2, 2019 | Regeneron Pharmaceuticals REGN | Award 323 sh | 323 |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.